EHA 2019

Area: Hematology

Location: Amsterdam, Netherlands

Date: June 13 to June 16

Description:

The 24th Congress of the European Hematology Association.


Search in Scientific Content:
Date
Filters:
The first-
3:49

The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: INTERIM phase 1B/2 results

Presenter: Mark Roschewski
Hematology
Breaking d
6:20

Breaking down diagnostic and treatment algorithms to aid in the selection of front-line de novo acute myeloid leukaemia therapy

Presenter: Christoph Röllig
Hematology
Rituximab
3:26

Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: results from a randomized HOVON-NORDIC Lymphoma group phase III study

Presenter: Pieternella Lugtenburg
Hematology
CPI-0610,
5:32

CPI-0610, a bromodomain and extraterminal domain (BET) inhibitor, reduces pro-inflammatory cytokines, bone marrow fibrosis and the number of transfusions in myelofibrosis patients

Presenter: Ronald Hoffman
Hematology
Targeting
1:45

Targeting aberrant DNA methylation as a novel and uniform therapeutic strategy for the treatment of T-cell acute lymphoblastic leukemia and lymphoma

Presenter: Morgan Thenoz
Hematology
ASCEND Pha
3:19

ASCEND Phase 3 study of acalabrutinib vs investigator's choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

Presenter: Paolo Ghia
Hematology
A randomiz
3:29

A randomized controlled phase III clinical trial comparing recombinant interferon alpha-2 vs. hydroxyurea in patients with myeloproliferative neoplasms -Three-year analysis of the DALIAH trial

Presenter: Trine Alma Knudsen
Hematology
Sotatercep
4:41

Sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anemia

Presenter: Prithviraj Bose
Hematology
Is iron ch
6:51

Is iron chelation really necessary in MDS?

Presenter: Eva Hellström Lindberg
Hematology
Complex ev
4:21

Complex evaluation of cellular and humoral immunity in patients with chronic lymphocytic leukemia

Presenter: Lukas Smolej
Hematology
NGS techno
6:29

NGS technologies in AML: Time to use in clinical care?

Presenter: Torsten Haferlach
Hematology
Large B-ce
11:60

Large B-cell lymphomas

Presenter: Umberto Vitolo
Hematology
Tipifernib
1:30

Tipifernib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL): preliminary results from an open-label, phase 2 study

Presenter: Francine Foss
Hematology
Results fr
3:01

Results from the randomized placebo- controlled phese 3 HOPE trial of voxelotor in adults and adolescents with sickle cell disease

Presenter: Jo Howard
Hematology
Immunother
4:20

Immunotherapy in relapsed/refractory multiple myeloma

Presenter: Enrique Ocio
Hematology
New therap
5:04

New therapies in AML

Presenter: Gunnar Juliusson
Hematology

EHA 2020

2020-06-11 - 2020-06-21
Online, Virtual

ESH 2020

2020-05-29 - 2020-06-01
Online, Virtual

ASH 2019

2019-12-07 - 2019-12-10
Orlando, United States

EMMA 2019

2019-01-31 - 2019-02-02
Vienna, Austria

ASH 2018

2018-12-01 - 2018-12-04
San Diego, United States

EHA 2018

2018-06-14 - 2018-06-17
Stockholm, Sweden

ASH 2017

2017-12-09 - 2017-12-12
Atlanta, United States

EHA 2017

2017-06-22 - 2017-06-25
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland